ADRB2 and myocardial infarction: Based on our results we assume that the reported increased mortality is rather a consequence of the concomitant heart disease than the conduction delay in itself as β-AR blockade basically shows positive effects on mortality in patients after myocardial infarction or in patients with congestive heart failure [48], [49].